KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Prepaid Assets (2016 - 2025)

Biomarin Pharmaceutical's Prepaid Assets history spans 17 years, with the latest figure at $185.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets fell 7.81% year-over-year to $185.8 million, compared with a TTM value of $185.8 million through Dec 2025, down 7.81%, and an annual FY2025 reading of $185.8 million, down 7.81% over the prior year.
  • Prepaid Assets for Q4 2025 was $185.8 million at Biomarin Pharmaceutical, down from $204.3 million in the prior quarter.
  • The five-year high for Prepaid Assets was $224.8 million in Q3 2023, with the low at $91.2 million in Q1 2021.
  • Average Prepaid Assets over 5 years is $155.0 million, with a median of $161.9 million recorded in 2024.
  • Year-over-year, Prepaid Assets tumbled 41.44% in 2021 and then skyrocketed 50.02% in 2023.
  • Tracing BMRN's Prepaid Assets over 5 years: stood at $110.4 million in 2021, then decreased by 5.36% to $104.5 million in 2022, then soared by 35.28% to $141.4 million in 2023, then soared by 42.54% to $201.5 million in 2024, then decreased by 7.81% to $185.8 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Prepaid Assets are $185.8 million (Q4 2025), $204.3 million (Q3 2025), and $177.2 million (Q2 2025).